Pfizer reaffirms 2026 guidance after CFO transition news

Pfizer (NYSE: PFE) reaffirmed its full-year 2026 financial guidance following the announcement of a Chief Financial Officer transition on June 18, 2026.

The company maintained its forecast for revenues in a range of $59.5 billion to $62.5 billion, and adjusted diluted earnings per share in a range of $2.80 to $3.00. The guidance was originally introduced on December 16, 2025, and was previously reaffirmed during Pfizer's first-quarter earnings call on May 5, 2026.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• HeartSciences (HSCS) files $200M mixed shelf
• Genco Shipping amends shareholder rights agreement, extends to 2027